{"task_id": "17e89b93cd1e5dae", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 437/464)", "text": "ischarge Issues\n429\n\n--- Page 451 [Image/Scan] ---\n\n--- Page 452 ---\nAppendix A\nADVANCED CARDIAC LIFE SUPPORT\nAmerican Heart Association (AHA), European Resuscitation Council (ERC), and International Liaison Committee\non Resuscitation (ILCOR) 2005 Guidelines. Circulation 2005; 112[Suppl I]:IV1 211\nBradycardia drugs\nAtropine 0 5 1 mg IV repeat q3\n5min, max total 0 04 mg/kg (ap\nproximately 3 doses), 2 2 5 \u00d7 IV\ndose down endotracheal tube in \n10 mL NS f needed   Unlikely \nbeneficial in third degree or Mobitz\ntype II block \nDopamine 5 20 \u00b5g/kg/min IV, after\nmax dose of atropine \nEpinephrine 2 10 \u00b5g/min IV, if \nsevere bradycardia with hypoten\nsion \nAsystole PEA DDx\nHypovolemia hypoxia \nHypothermia hyper/hypoK \nH+ (acidosis) \nTablets \nTamponade  \nTension pneumothorax \nThrombosis CAD \nThrombosis PE \nAsystole/PEA drugs\nEpinephrine 1 mg IV push, q3\n5min, or 2 2 5\u00d7 IV dose down\nendotracheal tube in 10 mL of NS\nfollowed by hyperven ilation if IV\nnot available\nAtropine 1 mg IV push, q3\n5min, max total 0 04 mg/kg\n(approximately 3 doses), 2 2 5\u00d7\nIV dose down endotracheal tube\nin 10 mL NS f needed\nVF/pulseless VT drugs\nEpinephrine 1 mg IV push, q3\n5min\nVasopressin 40 U IV push\u00d71\ndose \nAmiodarone 1st dose 300 mg\nIV push, 2nd dose 150 mg, max \ntotal 2 2 g/24 h\nLidocaine 1 5 mg/kg IV push,\nand repeat 0 5 0 75 mg/kg q5\n10min to max 3 mg/kg \nProcainamide 50 mg/min IV\nMgSO4 2 g IV if torsades de\npointes or suspect hypo Mg\nHCO3 2 amp IV push f hyper\nkalemia, metabolic acidosis,\nTCA overdose, barbiturate\noverdose, ASA daily, etc\nAvoid f respiratory acidosis\n \nTachycardia drugs\nAmiodarone 150 mg IV bolus over 10 min, then 1 mg/min (60 mg/h) for 6 h, \nfollowed by 0 5 mg/min (30 mg/h) for 18 h   Maximum total 2 2 g/24 h \nProcainamide 20 30 mg/min IV, maximum infusion at 17 mg/kg, maintenance at 1\n4 mg/min   Indicated particularly for WPW with AF (wide complex irregular achycardia)\nAdminister until maximum dose reached, dysrrhytmia suppressed, QRS widens >50%,\nor hypotension occurs \nAdenosine 6 mg rapid IV push, 2nd dose 12 mg, 3rd dose 12 mg   Indicated in PSVT\nAvoid if WPW with AF \nAmiodarone 150mg IV bolus over 10 min, q10 15min   Alternatively, infusion 360 mg\nover 6 h, then 540 mg over 18 h  Maximum total 2 2 g/24 h   Good for most SVT\n\u03b2-Blocker:  Metoprolol 5 mg IV q5min, may repeat \u00d72  Maximum total 15 mg, Labetalol\n10 mg IV q10min  Maximum total 150 mg\nCalcium channel blocker: Diltiazem 0 25 mg/kg (10 20 mg) IV over 2 min, 2nd \ndose 0 35 mg/kg (25 mg), then infusion at 5 10 mg/h   Verapam l 2 5 5 mg IV over 2\nmin, repeat 15 30 min   Avoid if WPW with AF \nDigoxin 0 4 0 6 mg IV, then 0 1 0 3 mg q6 8h   Then 0 125 0 5 mg IV/PO daily\nImportant Principles\nCPR\u2014ensure good compressions by allowing chest to recoil fu ly and minimizing interrupt ons.  Aim for 100 compressions per m nute for 2 m n each cyc e.  Continue until regain pulse.  \nThe focus for nitial resuscitation shou d be on per orming h gh-quality CPR.  Frequent pulse check, intubat on, central line insert on, and medicat ons may sometimes distract the team from \nthis important task \nAirway\u2014avoid hyperventilat on as this could increase ntrathoracic pressure.  Initial use of oropharyngeal airway with bag-valve mask is reasonable, with 2 breaths given after every 30 CPR \ncompress ons.  Once switched to advanced airway (laryngeal mask airway, combitube, or endotracheal tube), breaths should be given every 6 s \nAccess\u2014the preferred route is through a perpherial intravenous (IV) l ne, which can usually be estab ished easi y.  The ntraosseous (IO) route represents a second choice, while central \nl nes and endotracheal tube should be the last resort for medication access \nAssess ABC\nIf pulseless, proceed to CPR right away \nIf pulse present, check pulse, BP, O2 sat \nGive O2, monitor rhythm, IV access \nPulseless\nStart CPR \nTachycardia\n12 lead ECG \nBradycardia\n12 lead ECG \nAsystole, PEA\nVF/pulseless\nVT \nUnstable\nStable\nUnstable \nStable \nEpinephrine\n1 mg IV or \nVasopressin \n40 U IV \nReassess\nABC/rhythm \nCPR \u00d7 2 min \nthen \nDefibr llate x1  \n150\u2212200 J  \n(biphasic), \nor 360 J  \n(monophasic)\nEpinephrine 1 mg\nIV q3min, or \nVasopressin 40 U\nIV \u00d7 1\nAtropine\n1 mg IV f \nbradycardia \nReassess \nABC/rhythm \nReassess\nABC/rhythm \nDef brillate 360 J\n(monophasic)\nif stil VF/pulseless\nVT\nReassess\nABC/rhythm \nConsider amio\ndarone 300 mg IV,\nlidocaine, \n1 5 mg/kg IV, or \nMgSO4 2 g IV \nRepeat epi-\natropine \ncycle  \nq3\u22125min \nTx Causes \n12 lead ECG  \nNS 2 L IV \nHCO3 2 amp \nMgSO4 2 g IV \nChest \ndecom-\npression \nTransven-\nous pacing  \nPrimary AV  block\nType I and II \nSecondary AV block\nTertiary  AV block\nType II Secondary\n AV block\nTertiary  AV block\nPrimary AV  block\nType I Secondary \nAV block\nCease resuscita-\nion? \nReassess \nABC/rhythm \nDef brillate 360 J\n(monophasic)\nif stil VF/pulseless\nVT \nReassess\nABC/rhythm \nRepeat epi shock\u2212\ndrug shock cycle\nAtropine 0 5 mg IV\nTranscutaneous\npacemaker \nDopamine\n5\u221220 \u00b5g/kg/min IV\nor \nEpinephrine\n2\u221210 \u00b5g/min IV \nMonitor ABC\nTranscutaneous\npacemaker \nTransvenous\npacemaker\nPermanent pace\nmaker \nTransvenous\npacemaker\nNarrow complex\n(regular)\nAtrial (atrial \nflutter, ectopic),\nJunctional, \nPSVT (AVNRT,\northodromic \nAVRT WPW) \nIf rate >150, \nimmediate car-\ndioversion.  If \nrate <150, monitor \nABC and proceed \nwith cardioversion \nwhen rate >150 \nPremedicate \nMidazolam 1 mg \nIV q2\u22123min and\nFentanyl 50\u2212\n150 \u00b5g IV q5min \nEnsure\nIV access, O2 sat \nmonitor, intubation \nequipment, and \nsuction available\nSynchronized \ncardioversion\n30J, 70J, 100J, \n150J (biphasic) \nor\n50J, 100J, 200J,\n300J, 360J (mo\nnophasic) \nMonitor ABC, \nprepare to intubate\nand give anti-\narrhythmics prn \nNarrow complex\n(irregular)\nAF, Atrial flutter,\nMAT \nDiltiazem\n10\u221220 mg IV over\n2 min\nor\nMetoprolol \n5 mg IV,or\n Amiodarone\n 150 mg IV \nover 10 min, or\nDigoxin\n0 4\u22120 6 mg IV \n see ATRIAL \nFIBRILLATION\nfor further details\n(p  39) \nIf monomorphic \nVT and no heart \nfailure  \nAmiodarone  \n150 mg IV bolus \nover 10 min, or\nProcainamide \n20 mg/min (max \n17 mg/kg)\nIf polymorphic VT \nw/prolonged QT\nMgSO4 2 g IV \nIsoproterenol\n0.02\u22120.04 mg IV \npush \nOverdrive pacing\nVagal maneuvers\n(carotid massage\nValsalva) \nSynchronized \ncardioversion \n see ATRIAL \nFIBRILLATION \n(p  39) \nSynchronized \ncardioversion \n see unstable \ntachycardia \nSynchronized \ncardioversion \n see unstable \ntachycardia \nAdenosine 6 mg\nrapid IV push  \nMay repeat 12 mg\nup to 2\u00d7\nCheck    rhythm \nIf healthy heart\nDiltiazem  \n10\u221220 mg IV over\n2 min, or\nMetoprolol \n5 mg IV \nIf LV failure\nD ltiazem  \n10\u221220 mg IV over\n2 min, or\nDigoxin\n0 4\u22120 6 mg IV, or\nAmiodarone \n150 mg IV \nover 10 min \nCPR  2 min, IV\nAirway   Mx\n     CPR   2 min\n     CPR   2 min\n     CPR   2 min\n     CPR   2 min\nIV access \nAirway  Mx\nIV access \nWide complex\nVT\n(most common) \nSVT with BBB  \nAF with WPW \nantidromic AVRT\nD. Hui, Approach to Internal Medicine, DOI 10.1007/978 1 4419 6505 9 18,\n\u0002 Springer Science\u00feBusiness Media, LLC 2006, 2007, 2011\n431", "text_length": 6892, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 437/464)", "type": "chunk", "chunk_index": 436, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.849740", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.850529", "status": "pending"}